trimetrexate has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarris, AH | 1 |
| Phan, A | 1 |
| Duvic, M | 1 |
| Romaguera, J | 1 |
| McLaughlin, P | 1 |
| Mesina, O | 1 |
| King, K | 1 |
| Medeiros, LJ | 1 |
| Rassidakis, GZ | 1 |
| Samuels, B | 1 |
| Cabanillas, F | 1 |
1 trial available for trimetrexate and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Female; Humans; | 2002 |